ArticleJournal of advanced research2026
Melanin nanoparticles-loaded lactobacillus fermentum exosomes for targeted and visualized treatment of ulcerative colitis.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- Engineering Small Extracellular Vesicles for Colon-Targeted Delivery: Microenvironment-Responsive Design, Therapeutic Mechanisms, and Clinical Translation.International journal of nanomedicine · 2026Review
- Mammalian, plant, and gut microbiota-derived extracellular vesicles as emerging therapeutics for bone diseases.Frontiers in bioengineering and biotechnology · 2026Review
- Hydrogel-Shielded Ellagic Acid Nanoparticles Prolong Colonic Retention and Mitigate DSS-Induced Colitis via Reactive Oxygen Species Scavenging.Foods (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUlcerative colitis (UC) is chronic specific intestinal inflammation characterized by excessive reactive oxygen species, augmented inflammation, imbalanced microbiota and aberrant immune environment. However, conventional therapies are greatly limited due to the serious side effects and other technique problems. Multi-functional medicine should be designed and constructed to treat UC based on complex pathological mechanisms.
objectivesAntioxidant and microbiota regulator would be synergistically combined for the effective therapy of UC. MNPs-Lf-EVs, composed of melanin nanoparticles and Lactobacillus fermentum exosomes, would be developed for the treatment of UC through antioxidant and microbiota modulating effect.
methodsMNPs-Lf-EVs were constructed through ultrasonication crushing method. The ability of scavenging free radicals, reducing apoptosis, inhibiting inflammation and promoting cell migration was examined on intestinal epithelium and macrophage. The targeting distribution was tracked by fluorescence and photoacoustic imaging. The efficacy and underlying mechanisms were conducted on colitis mice through HE staining, protein expression level and 16S rRNA sequencing analysis.
resultsLf-EVs were extracted from Lactobacillus fermentum and melanin nanoparticles (MNPs) were synthesized and loaded into EVs to successfully prepare MNPs-Lf-EVs to attenuate UC. In vitro assays exerted the superior ability of MNPs-Lf-EVs to scavenge free radicals, reduce apoptosis, and regulate the expression of inflammatory cytokines. Both photoacoustic and fluorescence imaging results confirmed that MNPs-Lf-EVs could resist the harsh gastrointestinal environment to reach the inflammation colonic lesion and achieve colon-targeted visualized accumulation after oral administration. In vivo experiments demonstrated that MNPs-Lf-EVs effectively alleviated major symptoms, mitigated oxidative stress and inflammatory condition, and promoted the restoration of intestinal barrier. In addition, 16S rRNA sequencing data proved that MNPs-Lf-EVs could increase the diversity and species richness of intestinal microbiota.
conclusionNatural origin property and green fabrication process of MNPs-Lf-EVs in this study may provide a safer and efficacious therapeutic platform for the targeted and visualization treatment of UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.